D89.813
Graft-versus-host disease, unspecified
Clinical Classification Guidelines
Medical Intelligence & Overview
Graft-versus-host disease (GVHD) is a health condition that can occur after a person receives a transplant of bone marrow or stem cells. This disease arises when the donor cells attack the recipient's tissues and organs, recognizing them as foreign. The condition can affect various parts of the body, including the skin, liver, and gastrointestinal tract. When the specific cause or type isn't fully determined, it's classified as unspecified, such as with ICD-10 code D89.813. Recognizing and understanding GVHD is essential for managing symptoms and guiding treatment, especially in transplant recipients.
Causes & Symptoms
Clinical Causes: Receiving a transplant of bone marrow or stem cells from a donor (allogeneic transplant). Mismatch or difference in the tissue types (HLA incompatibility) between donor and recipient. The immune cells in the transplanted material attacking the recipient's tissues. Certain immunosuppressive therapy regimens that may contribute to immune dysregulation.
Key Symptoms: Skin rash, redness, or blistering, often on the palms, soles, or general body skin. Jaundice, which causes yellowing of the skin and eyes due to liver involvement. Diarrhea, abdominal pain, or cramping caused by gastrointestinal tract involvement. Swelling or tenderness in the liver area. Fever or chills accompanying other systemic symptoms. Unexplained weight loss or fatigue.
Diagnostic & Treatment
Diagnosis Path: Physical examination noting skin and organ involvement. Blood tests to evaluate liver function and overall immune status. Biopsies of affected tissues such as skin or gastrointestinal lining. Imaging studies if organ damage is suspected. Histopathological studies of tissue samples revealing characteristic signs of GVHD. Monitoring the patient's transplant history for recent procedures.
Treatment Protocols: Immunosuppressive medications like corticosteroids to control immune activity. Other drugs such as calcineurin inhibitors or methotrexate to dampen immune responses. Supportive care including wound management for skin lesions and nutritional support. Phototherapy or topical treatments for skin symptoms in some cases. Monitoring and treating organ-specific complications, such as jaundice or gastrointestinal disturbances. Adjusting immunosuppression levels based on response and side effects.
Clinical Advice & FAQs
Billing Guidance
Is D89.813 a billable ICD-10 code?
Yes, D89.813 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D89.813?
Clinical documentation must specify the nature of Graft-versus-host disease, unspecified and any associated comorbidities for accurate reporting.
Cite this Clinical Reference